Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Good times ahead
View:
Post by ScienceFirst on Jul 20, 2022 9:23am

Good times ahead

There seems to be a reason why Theralase didn't show up at ASCO (given where it is in its trial) and didn't put out a press release on the Ph. 1b patients #5 and #6 unbelievabe milestone that have been cancer free for 540 consecutive days with only 1 dose (and so, no maintenance).  They simply mentioned it in the MD&As.

I think it has to do with them not wanting to irritate some egos and wait for more Ph. 2 data before making an official splash, given the giant leap this treatment will allow.

As per the recent AUA2022 articles I posted this morning, you can see how our treatment would be amazingly disruptive.  I assume that maintenance schedules are bringing a lot of revenues to urologists.  This could be an issue for some of them.  We'll have to see how our treatment is received, just on that simple factor.  Money is something that sometimes become important to some.
Comment by Mongoose1975 on Jul 20, 2022 12:34pm
I can definitely see how that could potentially "irritate some egos" Growing up, I have often heard the idea thrown around (guilty of it myself) that the cure for cancer is out there. However, once shown to the world the multi billion/trillion+ dollar industry called Cancer would be no more. Treatments costing as much as a luxurious car taken 5, 10, 12 + times would be no more. Hospitals ...more  
Comment by Rumpl3StiltSkin on Jul 20, 2022 12:55pm
Yes, something we've discussed in the past. TLT certainly doesn't seem a threat to anyone now. At this SP, sitting on this exchange, with our current data... Actually if the data holds it wouldn't be awful...  It will be ~10yrs before TLT's ACT will be 'the cure' There is a long road ahead. Their piece of NMIBC will be enuf to get SP up once it is approved. Then we' ...more  
Comment by Eoganacht on Jul 20, 2022 1:11pm
I think it's more likely the thick wallets will come out. If pdt proves to be the anti-cancer technology of the future why not just buy out Theralase and use the IP as a tool against your competitors. Competing pharmas may have to scramble to find their own pdt technology to stay in the game.
Comment by ScienceFirst on Jul 20, 2022 1:22pm
Big pharmas CEO all have stock options as an incentive to grow their market shares over competition. So one of them will make a move faster than its competitors.  #1 will want to stay #1 and #2 will want to shift #1, etc ...  That's a natural economic law. All industries have evolved, over the risk of disappearing, shifted by competition. LASIK didn't killed the eyeglasses ...more  
Comment by ScienceFirst on Jul 20, 2022 2:01pm
Considering that PDT is not an established technology yet in oncology, our time will come on clearer data that leaves no doubt, that shows where we can fit over competition. We're getting closer and closer to that moment and it would already have happened if our first 12 Ph. 2 patients would have been properly dosed.  But this issue could even be seen as positive if the FDA wants to make ...more  
Comment by menoalittle on Jul 20, 2022 1:25pm
>>  TLT certainly doesn't seem a threat to anyone now. Perhaps.  Then again, maybe it is, and that's why... >> At this SP, sitting on this exchange, with our current data... 
Comment by langosta on Jul 20, 2022 2:30pm
I'm not impressed with Big Pharmas. Their primary function always is "Profits", at any cost. There is a tendency to forget that they are in a business and are not some group of benevolent organizations. If there were some discovery for a deadly disease that was readily obtainable in the natural world and was available to everyone who required it then the big boys would do their best ...more  
Comment by ScienceFirst on Jul 20, 2022 2:33pm
Big pharmas model had evolved over the years.  They invest less in R&D to rather scout the planet for the best technologies brought by biotechs.  
Comment by thadeush on Jul 20, 2022 2:06pm
I know nothing, but have watched too many movies. What would Big Pharma pay a doctor to administer Theralase's treatment IMproperly? I've been told safeguards are in place, but I wouldn't put it past them to Epstein the trial if they could get away with it.
Comment by ScienceFirst on Jul 20, 2022 2:22pm
In Canada, all provinces within their systems have instances that assess the pros and cons of new treatments and make recommandations to the Ministers of Health.   Health ministers represent close to 50% of the provinces budgets so they have an incentive to go with the most productive and efficient technologies. Academic hospitals like Princess Margaret Cancer Center and the McGill ...more  
Comment by CAinPlap on Jul 20, 2022 4:06pm
I agree with you and Mongoose that Big Pharma will do anything to protect their golden goose. I wonder what our results would look like without the underdosing of first 12? Some do not like this being brought up but to think its not a possibility is naive.
Comment by fredgoodwinson on Jul 20, 2022 4:45pm
Most unusual given the long pause in Phase IB so as to - highly successfully - optimise the treatments for 5 & 6 via ithe most ntense attention to the process and then a complete balls-up of the first 12 at the start of Phase II at a time when attention to correct treatment could not have been more critical - and all still entirely unexplained. If recruitment had been any quicker - and if ...more  
Comment by ScienceFirst on Jul 20, 2022 5:17pm
Lets not fall into the easy trap of plot theories against big pharmas as they are all listed on stock exchanges, so all required to perform.  A CEO that doesn't perform is ousted.  And loses its stock options.  Pure and simple.  Each of them are free to go chase the best technologies around to increase their market shares, otherwise, one of their competitors will shift them ...more  
Comment by ScienceFirst on Jul 20, 2022 5:21pm
Lets not fall into the easy trap of plot theories against big pharmas as they are all listed on stock exchanges, so all required to perform.  A CEO that doesn't perform is ousted.  And loses its stock options.  Pure and simple.  Each of them is free to go chase the best technologies around to increase their market shares, otherwise, one of their competitors will shift them. ...more  
Comment by ScienceFirst on Jul 20, 2022 2:12pm
Ontario will be the first province to recommend and cover the treatment, given its investment in TLT's work and the medical tourism opportunity.   Insurance companies in the US will also have a huge incentive to cover such treatment.  Public health systems (Canada, Europe, etc ...) will also have huge incentives too to recommend such treatment.
Comment by ScienceFirst on Jul 20, 2022 9:09pm
Funding information Theralase Technologies Inc; Ontario Ministry of Health and Long Term Care for Princess Margaret Cancer Centre _______________________ ScienceFirst - (7/20/2022 2:12:12 PM) RE:Good times ahead Ontario will be the first province to recommend and cover the treatment, given its investment in TLT's work and the medical tourism opportunity.    ...more  
Comment by ScienceFirst on Jul 20, 2022 9:11pm
Acknowledgement: These studies were funded in part by Theralase Inc. Toronto, Ontario and the Ontario Ministry of Health and Long Term Care
Comment by Pandora on Jul 21, 2022 9:29am
Off topic but possible move in a big pharma. https://insiderfinancial.com/glaxos-new-focus-after-haleon-spinoff-shines-a-light-on-cytodyn-otcmkts-cydy-as-a-takeover-target/183360/
Comment by ScienceFirst on Jul 21, 2022 10:02am
Yeo!  Perfect example of big pharmas scouting for future platforms. I know the story of CYDY.  Molecule with amazing potential but with everything to be officially back by clear clinical data.   Things can positively turn for the better when you least expect it sometimes.     ____________   Pandora - (7/21/2022 9:29:48 AM) RE:RE:RE:RE ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250